How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

101,372 results for

Cancer Prevention

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Second malignant neoplasms after childhood non-central nervous system embryonal tumours in North America: A population-based study. (Abstract)

Second malignant neoplasms after childhood non-central nervous system embryonal tumours in North America: A population-based study. Few studies in North America have quantified the risks of second malignant neoplasms (SMNs) among survivors of childhood non-central nervous system (non-CNS) embryonal tumours due to their rarity. We aimed to investigate these risks by combining population-based data from the United States of America and Canada.We evaluated patients with childhood non-CNS embryonal (...) ). Most site-specific SIRs were significantly increased, ranging from 36 (95% CI: 26-49) for bone and joint cancer to 3.1 (95% CI: 1.5-5.2) for brain tumour. The risk for second malignancies declined as the time elapsed from the first primary diagnosis and was less prominent for patients first diagnosed at age 1-4 years. Notably, rhabdomyosarcoma survivors had a higher risk for SMNs than those with other first primaries. The overall cumulative incidence of SMNs was 1.0% at 10 years, increasing to 2.2

2017 European Journal of Cancer

2. AIM Clinical Appropriateness Guidelines for Molecular Testing of Solid and Hematologic Tumors and Malignancies

or Thrombocytosis 17 Primary Myelofibrosis 18 Genetic Testing for Hematologic Malignancy 18 Minimal Residual Disease (MRD) Genetic Testing 18 Solid Tumor Testing 19 NTRK Fusion Testing 19 PIK3CA Testing 20 Breast Cancer 20 Lung Cancer 22 Cell-Free Tumor Testing 23 Cancer of Unknown Primary/Occult Neoplasm 23 Pancreatic Cancer 24 Prostate Cancer 25 Thyroid Cancer 26 Cancer Screening 26 Indeterminate Thyroid Nodules 26 Colorectal Cancer Screening 28 Professional Society Guidelines 29 PROPRIETARY Guidelines (...) . All Rights Reserved. 6 ? Hepatobiliary cancer ? Kidney cancer ? Malignant pleural mesothelioma ? Merkle cell carcinoma ? Multiple myeloma ? Neuroendocrine and adrenal tumors - including gastrointestinal and lung ? Non-epithelial ovarian cancers or borderline epithelial tumors (low malignant potential) ? Occult primary ? Pancreatic cancer ? Prostate cancer - post-diagnosis gene expression classifiers ? Skin cancer - basal and squamous cell ? Small cell lung cancer ? T-cell lymphoma: cutaneous

2020 AIM Specialty Health

3. Incidence and Risk of Second Primary Malignant Neoplasm After a First Head and Neck Squamous Cell Carcinoma. Full Text available with Trip Pro

Incidence and Risk of Second Primary Malignant Neoplasm After a First Head and Neck Squamous Cell Carcinoma. Second primary malignant neoplasms (SPMNs) are the leading cause of death in survivors of head and neck squamous cell carcinoma (HNSCC). Recently, human papillomavirus (HPV) has emerged as a risk factor for oropharyngeal squamous cell carcinoma and has different prognosis from classic tobacco/alcohol-associated HNSCC. This suggests that there also may be different risks and burden (...) . Patients were grouped into 2 cohorts: potentially HPV-associated HNSCC, and non-HPV-associated HNSCC.The primary outcome was incidence of SPMN (defined as the first subsequent primary cancer occurring at least 2 months after first cancer diagnosis). Excess SPMN risk was calculated using relative (standardized incidence ratios [SIRs]) and absolute (excess absolute risk [EAR] per 10 000 person-years at risk [PYR]).A total of 109 512 patients with HNSCC (mean [SD] age, 61.9 [12.1] years; 83 305 [76.1

2018 JAMA otolaryngology-- head & neck surgery

4. AIM Clinical Appropriateness Guidelines for Molecular Testing of Solid and Hematologic Tumors and Malignancies

as outlined in the criteria in the NCCN ® Clinical Practice Guidelines in Oncology (NCCN Guidelines ® ), Prostate Cancer Early Detection. Confirmed Malignancy Gene expression or molecular profiling assays for confirmed prostate tumors are not medically necessary. Thyroid Cancer Confirmed or Highly-Suspected Thyroid Cancer BRAF V600E mutation analysis is medically necessary in cases with confirmed or highly-suspected follicular thyroid carcinoma, papillary thyroid carcinoma, medullary thyroid carcinoma (...) Use Criteria 3 National Comprehensive Cancer Network® (NCCN®) Criteria* 4 Polycythemia Vera 5 Essential Thrombocythemia or Thrombocytosis 5 Primary Myelofibrosis 5 Breast Cancer 6 Cancer of Unknown Primary/Occult Neoplasm 7 Prostate Cancer 7 Screening 7 Confirmed Malignancy 7 Thyroid Cancer 7 Confirmed or Highly-Suspected Thyroid Cancer 7 Cytologically Indeterminate Thyroid Nodule 7 Colorectal Cancer Screening 8 CPT Codes 8 Background 12 Myeloproliferative Disorders 12 Polycythemia Vera 12

2019 AIM Specialty Health

5. Diabetes and Weight Loss Are Associated With Malignancies in Patients With Intraductal Papillary Mucinous Neoplasms. Full Text available with Trip Pro

Diabetes and Weight Loss Are Associated With Malignancies in Patients With Intraductal Papillary Mucinous Neoplasms. The role of diabetes in intraductal papillary mucinous neoplasms (IPMNs) is not known. We investigated the prevalence of diabetes among patients with resected IPMNs and the association between diabetes, clinical and morphological features, and high-grade dysplasia or invasive cancer.We collected clinical, pathology, laboratory, and demographic data from 134 patients who underwent (...) involvement and high-grade dysplasia or invasive carcinoma. Studies are needed to determine the relationship between diabetes and progression of IPMNs, which might lead to strategies for early detection and prevention of invasive cancer. Findings from this study should be considered in the guidelines for management of IPMN.Copyright © 2020 AGA Institute. Published by Elsevier Inc. All rights reserved.

2020 Clinical Gastroenterology and Hepatology

6. A Case of Carcinoid Syndrome Due to Malignant Metastatic Carcinoid Tumor with Carcinoid Heart Disease Involving Four Cardiac Valves Full Text available with Trip Pro

A Case of Carcinoid Syndrome Due to Malignant Metastatic Carcinoid Tumor with Carcinoid Heart Disease Involving Four Cardiac Valves BACKGROUND Carcinoid tumor, benign, low-grade malignant, and high-grade malignant, can be associated with the release of vasoactive substances that cause symptoms including cutaneous flushing, diarrhea, and bronchospasm. In 50-60% of patients with carcinoid syndrome, the vasoactive substances cause fibrosis of the pulmonary and tricuspid heart valves which lead (...) appendiceal carcinoid tumor with bilateral ovarian metastases. Post-operatively, a computed tomography (CT) scan showed cardiomegaly. Transthoracic echocardiography showed morphologic changes that affected all four heart valves, consistent with carcinoid heart disease but without a patent foramen ovale (PFO). The patient was evaluated for valve replacement surgery, but surgery was not performed due to the degree of heart failure. CONCLUSIONS This report describes a rare case of carcinoid heart disease

2018 The American journal of case reports

7. Anti-infective Vaccination Strategies in Patients with Hematologic Malignancies or Solid Tumors - Guideline of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO). Full Text available with Trip Pro

Anti-infective Vaccination Strategies in Patients with Hematologic Malignancies or Solid Tumors - Guideline of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO). Infectious complications are a significant cause of morbidity and mortality in patients with malignancies specifically when receiving anticancer treatments. Prevention of infection through vaccines is an important aspect of clinical care of cancer patients. Immunocompromising (...) effects of the underlying disease as well as of antineoplastic therapies need to be considered when devising vaccination strategies. This guideline provides clinical recommendations on vaccine use in cancer patients including autologous stem cell transplant recipients, while allogeneic stem cell transplantation is subject of a separate guideline. The document was prepared by the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO) by reviewing

2018 Annals of Oncology

8. Clinico-pathological features and survival of patients with malignant exocrine pancreatic neoplasms: The AC Camargo Cancer Center experience. Full Text available with Trip Pro

Clinico-pathological features and survival of patients with malignant exocrine pancreatic neoplasms: The AC Camargo Cancer Center experience. Pancreatic cancer plays an important role in cancer-related mortality. Few studies have been performed in Brazil to characterize patients affected by this disease. We aimed to describe the clinico-pathological characteristics and the survival of patients with pancreatic cancer seen at AC Camargo Cancer Center (ACCCC).We included patients ≥ 18-year old (...) , with a histologically confirmed diagnosis of exocrine pancreatic cancer, that attended at least one visit at ACCCC from 2008 to 2016.The study included 739 patients. Median age at diagnosis was 64 years. Most patients were male. About 5% presented a family history of pancreatic cancer. A total of 40% had diabetes and 51.4% presented with ECOG performance status 1. Tumors most often arose in the pancreatic head and roughly half of the patients had metastatic disease at presentation. Median overall survival

2018 Journal of Surgical Oncology

9. AIM Clinical Appropriateness Guidelines for Molecular Testing of Solid and Hematologic Tumors and Malignancies

, Inc. All Rights Reserved. 14 Cancer of Unknown Primary/Occult Neoplasm Occult neoplasms, or cancers of unknown primary, are defined as histologically proven metastatic malignant tumors whose primary site cannot be identified during pretreatment evaluation. These may have a wide clinical presentation and typically a poor prognosis. Several laboratories offer gene expression profiling or NGS tests to aid in the identification of the tissue of origin of a metastatic tumor. NCCN ® Clinical Practice (...) the prevalence of cancer in the examined population, or if the local malignancy rate is high at baseline" (Ferris et al., 2015). The rate of diagnosis of a follicular variant of papillary thyroid cancer has been on the rise and is now the most common variant of PTC. In early 2017, the American Thyroid Association (Haugen et al., 2017) recommended a change in nomenclature from follicular variant of papillary thyroid carcinoma (FVPTC) to noninvasive follicular thyroid neoplasm with papillary-like nuclear

2017 AIM Specialty Health

10. Multiple Primary Malignant Neoplasms in an Elderly Patient Full Text available with Trip Pro

Multiple Primary Malignant Neoplasms in an Elderly Patient Only a few case reports to date have described patients with three or more cancers. However, the incidence of multiple primary malignancies is increasing due to the improved survival of cancer patients, the prolonged lifespan of the general population, and better diagnostic techniques. This report describes a 73-year-old woman with primary breast, rectal squamous cell, and renal cell carcinomas. This case is unique because, in addition (...) to having three primary malignancies, this patient had rectal squamous cell carcinoma-one of the rarest types of rectal cancer. We discuss screening and prevention of multiple malignancies and rectal squamous cell carcinoma, as well as methods for managing these patients.

2018 Cureus

11. PPA1 regulates tumor malignant potential and clinical outcome of colon adenocarcinoma through JNK pathways Full Text available with Trip Pro

PPA1 regulates tumor malignant potential and clinical outcome of colon adenocarcinoma through JNK pathways Colorectal cancer (CRC) represents one of the most prevalent malignancies and the third leading cause of cancer death worldwide. Inorganic pyrophosphatase (PPA1) is an enzyme that catalyzes the hydrolysis of pyrophosphate to inorganic phosphate, therefore participates in the energy metabolism. Proteomic studies have demonstrated the up-regulated expression of PPA1 in various tumors (...) enzymatic studies, which identified that PPA1 can directly dephosphorylate pJNK1, while showed no catalytic activity towards pERK or p-p38 proteins. Moreover, overexpression of PPA1 enhanced cell viability through JNK-p53 signaling pathways, and it may also prevent cell apoptosis by inhibiting Bcl-2 and Caspase-3 cleavage. To our knowledge, this is the first study demonstrated the expression and clinical significance of PPA1 in colon cancer, which also provided evidence that figuring out PPA1 specific

2017 Oncotarget

12. Breast phyllodes tumors recruit and repolarize tumor-associated macrophages via secreting CCL5 to promote malignant progression which can be inhibited by CCR5 inhibition Therapy. (Abstract)

Breast phyllodes tumors recruit and repolarize tumor-associated macrophages via secreting CCL5 to promote malignant progression which can be inhibited by CCR5 inhibition Therapy. Malignant phyllodes tumor (PT) is a fast-progression neoplasm derived from periductal stromal cells of the breast, which currently still lack effective treatment strategies. Our previous studies showed that the high density of tumor-associated macrophages (TAM) plays an important role in the malignant progression (...) to further promote the aggressive phenotype of malignant PTs by enhancing and maintaining the myofibroblast differentiation and invasion in vitro and in vivo. In a murine PDX model of human malignant PTs, the CCL5-CCR5 axis blocked by maraviroc, an FDA-proved CCR5 inhibitor, prevented recruitment of monocytes to the tumor and dramatically suppressed tumor growth.Our findings indicate that malignant PTs recruit and repolarize TAMs through a CCL5-CCR5-driven signaling cascade. Thus, a positive feedback

2019 Clinical Cancer Research

13. Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma

foreign or diseased cells) to an anti-cancer drug. The antibody is used to recognize tumor cells so the anti-cancer drug can kill them. Condition or disease Intervention/treatment Phase Pleuropulmonary Blastoma Recurrent Malignant Peripheral Nerve Sheath Tumor Recurrent Neuroblastoma Recurrent Rhabdomyosarcoma Recurrent Synovial Sarcoma Wilms Tumor Other: Laboratory Biomarker Analysis Biological: Lorvotuzumab Mertansine Other: Pharmacological Study Phase 2 Detailed Description: PRIMARY OBJECTIVES: I (...) of the malignancies listed below at original diagnosis or at relapse Primary strata Wilms tumor Rhabdomyosarcoma Neuroblastoma Secondary strata: miscellaneous CD56-expressing tumors: Pleuropulmonary blastoma Malignant peripheral nerve sheath tumor (MPNST) Synovial sarcoma Patients must have radiographically measurable disease (with the exception of those with neuroblastoma) Measurable disease is defined as the presence of at least one lesion on magnetic resonance imaging (MRI) or computed tomography (CT) scan

2015 Clinical Trials

14. Malignant tumours in urban Ghana: evidence from the city of Kumasi. Full Text available with Trip Pro

Malignant tumours in urban Ghana: evidence from the city of Kumasi. Data from population-based cancer registries (PBCRs) are a useful resource for estimating the incidence of cancers. PBCR data is useful in the planning and implementation of cancer prevention and control strategies. Ghana's plan for control of non-communicable diseases recognises the need for good quality data to facilitate the attainment of set goals.We reviewed data from the Kumasi Cancer Registry for the year 2015. Data (...) collected included clinical and demographic information, laboratory reports and source of case information. Data was entered into the Canreg-5 software. Data was initially analysed using Canreg-5 to estimate the incidence and age standardised rates (ASR) for various tumours. Data was also exported to Microsoft Excel for further analysis using Epi Info version 7.1.4. Microsoft Excel was used to generate charts and graphs. Aggregated data for the years 2013 and 2014 were also analysed for trends in cancer

2019 BMC Cancer

15. Second Primary Malignant Neoplasms and Survival in Adolescent and Young Adult Cancer Survivors Full Text available with Trip Pro

Second Primary Malignant Neoplasms and Survival in Adolescent and Young Adult Cancer Survivors Although the increased incidence of second primary malignant neoplasms (SPMs) is a well-known late effect after cancer, few studies have compared survival after an SPM to survival of the same cancer occurring as first primary malignant neoplasm (PM) by age.To assess the survival impact of SPMs in adolescents and young adults (AYAs) (15-39 years) compared with that of pediatric (<15 years) and older (...) % for secondary breast carcinoma, 15% for secondary thyroid carcinoma, and 13% for secondary soft-tissue sarcoma. Survival by SPM status was significantly worse in younger vs older patients for thyroid, Hodgkin lymphoma, non-Hodgkin lymphoma, acute myeloid leukemia, soft-tissue sarcoma, and central nervous system cancer. Adolescents and young adults with secondary Hodgkin lymphoma (hazard ratio [95% CI], 3.5 [1.7-7.1]); soft-tissue sarcoma (2.8 [2.1-3.9]); breast carcinoma (2.1 [1.8-2.4]); acute myeloid

2017 JAMA oncology

16. Ovarian Low Malignant Potential Tumors Treatment (PDQ®): Patient Version

Low Malignant Potential Tumors (Stage I and II) is the for early . The type of surgery usually depends on whether a woman plans to have children. For women who plan to have children, surgery is either: ; or . To prevent of disease, most doctors recommend surgery to remove the remaining when a woman no longer plans to have children. For women who do not plan to have children, treatment may be and . Use our to find NCI-supported cancer clinical trials that are accepting patients. You can search (...) Ovarian Low Malignant Potential Tumors Treatment (PDQ®): Patient Version Ovarian Low Malignant Potential Tumors Treatment (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf Warning: The NCBI web site requires JavaScript to function. Search database Search term Search NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health. PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002-. PDQ Cancer Information

2018 PDQ - NCI's Comprehensive Cancer Database

17. Second primary malignancy in patients with esophageal adenocarcinoma and squamous cell carcinoma. Full Text available with Trip Pro

analysis to evaluate their clinical utility. Age group and SEER historic stage were significantly associated with second primary malignancy risk after diagnosis of esophageal adenocarcinoma and squamous cell carcinoma. Saving positive lymph nodes and distant metastasis were significant factors in the adenocarcinoma group, and marital status, tumor location, and chemotherapy were significant factors in the squamous cell carcinoma group. Calibration plots show good concordance between predicted (...) adenocarcinoma and squamous cell carcinoma, respectively) at which the clinical net benefit of the risk model was larger than those of hypothetical all-screening and no-screening scenarios. Our nomograms enable selection of patient populations at high risk for a second primary malignancy and thus will facilitate the design of prevention trials for affected populations.

2019 Medicine

18. Febuxostat for Tumor Lysis Syndrome Prevention in Hematological Malignancies of Paediatric Patients and Adults

Febuxostat for Tumor Lysis Syndrome Prevention in Hematological Malignancies of Paediatric Patients and Adults Febuxostat for Tumor Lysis Syndrome Prevention in Hematological Malignancies of Paediatric Patients and Adults - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved (...) studies (100). Please remove one or more studies before adding more. Febuxostat for Tumor Lysis Syndrome Prevention in Hematological Malignancies of Paediatric Patients and Adults (FLORET) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov

2018 Clinical Trials

19. Use of microwave ablation in the treatment of patients with multiple primary malignant tumors Full Text available with Trip Pro

. Preventive radiotherapy of the whole brain was performed after complete remission of the lung disease. Seven years after diagnosis, follow-up computed tomography revealed masses in both the liver and kidney. Subsequent percutaneous biopsy confirmed hepatocellular carcinoma in the liver and renal clear cell carcinoma in the kidney. The patient received microwave ablation for the treatment of both liver and renal tumors, and is doing well with no recurrence after two years of follow-up.© 2017 The Authors (...) Use of microwave ablation in the treatment of patients with multiple primary malignant tumors A 56-year-old man was admitted to our hospital in 2007, complaining of an irritating cough. Computed tomography examination demonstrated a mass in the right lung and enlargement of the hilar and mediastinal lymph nodes. Small cell lung cancer was confirmed by pathological examination after fibro-bronchoscope biopsy. The patient was treated with received sequential chemotherapy and radiotherapy

2017 Thoracic cancer

20. Transcatheter arterial chemoembolization improves the resectability of malignant breast phyllodes tumor with angiosarcoma component: a case report. Full Text available with Trip Pro

Transcatheter arterial chemoembolization improves the resectability of malignant breast phyllodes tumor with angiosarcoma component: a case report. A giant phyllodes tumor of the breast is a rare fibroepithelial lesion, and its treatment is controversial. Many case reports have reported performing skin graft reconstruction after tumor excision. Chest wall resection may be required if the tumor has invaded the chest muscle layer. We speculated that transcatheter arterial chemoembolization (TACE (...) ) can improve the resectability of malignant phyllodes tumor of the breast without requiring skin grafting. The English literature contains only one case report similar to our experience.We report a rare case of a 51-year-old woman who had a giant malignant phyllodes tumor with heterologous sarcomatous differentiation in her right breast. The tumor was 19.43 × 12.98 × 21.47 cm. Whole-body computed tomography (CT) and bone scan did not reveal distant metastasis. Chest magnetic resonance imaging

2019 BMC Surgery

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>